Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.
Fiche publication
Date publication
décembre 2019
Journal
Clinical nutrition (Edinburgh, Scotland)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr QUILLIOT Didier
Tous les auteurs :
Joly F, Seguy D, Nuzzo A, Chambrier C, Beau P, Poullenot F, Thibault R, Armengol Debeir L, Layec S, Boehm V, Lallemand J, Quilliot D, Schneider SM
Lien Pubmed
Résumé
Teduglutide, a GLP-2-analog, has proven effective in two placebo-controlled studies in reducing parenteral support (PS) in patients with short bowel syndrome-associated intestinal failure (SBS-IF) after 24 weeks. The aim of this study was to describe in a real-life situation the effects of teduglutide treatment and their predictive factors.
Mots clés
GLP2- receptor agonist, Inflammatory bowel disease, Intestinal failure, Parenteral nutrition, Short-gut syndrome
Référence
Clin Nutr. 2019 Dec 23;: